Thu, May 15, 9:28 PM (34 days ago)
### Summary of Windtree Therapeutics, Inc. (WINT) Q1 2025 Financial Performance **Company Overview:** Windtree Therapeutics, Inc. (WINT) is a biotechnology company focused on advancing innovative therapies for critical conditions and diseases. Their portfolio includes istaroxime, SERCA2a activators, rostafuroxin, and aPKCi inhibitors. The company also has a licensing business model and plans to generate revenue through acquisitions of small companies with FDA-approved products. **Financial Health:** - **Revenue:** Not explicitly mentioned, but the company is in a development phase. - **Profit Margins:** The company reported a net loss of $4.0 million for Q1 2025, compared to a net income of $10.2 million in Q1 2024, which included a $14.5 million gain on debt extinguishment. - **Cash Flow:** The company had cash and cash equivalents of $1.2 million as of March 31, 2025, and current liabilities of $6.5 million. They expect to fund operations through May 2025. - **Earnings Changes:** The net loss for Q1 2025 was $4.0 million, compared to a net income of $10.2 million in Q1 2024. **Quarterly Performance Discussion:** - **Operating Expenses:** Total operating expenses were $4.09 million for Q1 2025, down from $4.405 million in Q1 2024. - **Research and Development:** Expenses were $2.27 million, slightly up from $2.253 million in Q1 2024. - **General and Administrative:** Expenses were $1.82 million, down from $2.152 million in Q1 2024. - **Other Income/Expense:** Included a $22,000 loss on debt extinguishment and a $134,000 change in fair value of common stock warrant liability. **Trends and Uncertainties:** - **Funding:** The company faces significant funding challenges and may need to secure additional capital through public or private offerings, convertible debt financings, or strategic transactions. - **Clinical Trials:** The company's ability to complete clinical trials depends on securing adequate resourcing through financing efforts or business development activities. - **Market Conditions:** The company is attentive to evolving global economic conditions, including uncertainties related to international trade policies, tariffs, and supply chain dynamics. **Future Operations Impact:** - **Strategic Initiatives:** The company plans to become a revenue-generating biotech company through acquisitions of small companies with FDA-approved products. - **Clinical Development:** Continued development of product candidates, including istaroxime for cardiogenic shock and acute heart failure, and preclinical SERCA2a activators for heart failure. **Conclusion:** Windtree Therapeutics, Inc. is in a critical phase of development, facing significant financial challenges and uncertainties. The company's strategic initiatives and ability to secure additional funding will be crucial for its future operations and success.